Edition:
United States

Pfizer Inc (PFE.N)

PFE.N on New York Stock Exchange

41.01USD
10:59am EDT
Change (% chg)

$0.30 (+0.74%)
Prev Close
$40.71
Open
$40.82
Day's High
$41.08
Day's Low
$40.65
Volume
1,270,156
Avg. Vol
6,511,917
52-wk High
$41.63
52-wk Low
$32.33

Select another date:

Fri, Aug 10 2018

J&J loses bid to dismiss Pfizer antitrust case over Remicade

A federal judge on Friday rejected Johnson & Johnson's bid to dismiss a lawsuit by Pfizer Inc claiming that the drugmaker had engaged in an anticompetitive scheme to shield its blockbuster rheumatoid arthritis drug Remicade from competition.

Allergan sues Pfizer over costs of opioid litigation

Allergan Plc on Thursday sued Pfizer Inc to require its rival to cover any damages it is forced to pay as a result of hundreds of lawsuits claiming Allergan deceptively marketed an opioid it acquired from a company Pfizer bought.

UPDATE 1-Allergan sues Pfizer over costs of opioid litigation

Aug 2 Allergan Plc on Thursday sued Pfizer Inc to require its rival to cover any damages it is forced to pay as a result of hundreds of lawsuits claiming Allergan deceptively marketed an opioid it acquired from a company Pfizer bought.

CORRECTED-Allergan sues Pfizer over costs of opioid litigation

Aug 2 Allergan Plc on Thursday sued Pfizer Inc to force its rival to cover any damages Allergan is forced to pay as a result of hundreds of lawsuits claiming it deceptively marketed an opioid it acquired from a company Pfizer bought.

Pfizer CEO expects Trump to eliminate drug rebates

Pfizer Inc Chief Executive Ian Read said on Tuesday he believes the Trump administration intends to stop the practice of allowing rebates on prescription drug purchases, suggesting that U.S. drug pricing reforms may focus on middlemen rather than drugmakers. | Video

Pfizer CEO believes U.S. will eliminate rebates on prescription drugs

NEW YORK Pfizer Inc Chief Executive Ian Read said on Tuesday that he believes the Trump administration intends to eliminate rebates on prescription drug purchases, but he does not know how quickly such a policy could be implemented.

UPDATE 4-Pfizer CEO expects Trump to eliminate drug rebates

July 31 Pfizer Inc Chief Executive Ian Read said on Tuesday he believes the Trump administration intends to stop the practice of allowing rebates on prescription drug purchases, suggesting that U.S. drug pricing reforms may focus on middlemen rather than drugmakers.

Pfizer CEO believes U.S. will eliminate rebates on prescription drugs

NEW YORK, July 31 Pfizer Inc Chief Executive Ian Read said on Tuesday that he believes the Trump administration intends to eliminate rebates on prescription drug purchases, but he does not know how quickly such a policy could be implemented.

Pfizer profit rises 26 pct

July 31 Pfizer Inc reported a 26 percent rise in quarterly profit on Tuesday, driven by higher sales of its drugs, including breast cancer treatment Ibrance.

UPDATE 1-Trump thanks Novartis, Pfizer for not raising drug prices

WASHINGTON, July 19 U.S. President Donald Trump thanked two major drug companies on Thursday for not raising their prices and said his administration was working toward substantially cutting prescription-drug prices.

Select another date: